Projects
A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases. University of Antwerp
Investigating the biomarker potential and pathological role of neuronal- and bacterial- derived extracellular vesicles in Parkinson’s disease. Ghent University
Accumulating evidence indicates that extracellular vesicles (EVs) represent a highly interesting biomarker source. Indeed, neuronal-derived EVs (nEVs) separated from peripheral sources provide a snapshot of ongoing pathological changes in the brain whereas bacterial EVs (bEVs) have shown to reflect microbial dysbiosis. Interestingly, both neuronal changes and microbial dysbiosis are evident in Parkinson’s disease (PD) patients. Additionally, ...
A mucin isoform-based biomarker assay to improve follow-up and treatment of inflammatory bowel diseases (IBD) and gastrointestinal (GI) cancers. University of Antwerp
Validating the application of a first-in-class human serum-functional immunodynamic status (sFIS) assay as bona fide immuno-oncology biomarker KU Leuven
Automation of a mucin mRNA isoform-based biomarker platform to monitor patients with inflammatory bowel diseases. University of Antwerp
Breath analysis as a non-invasive biomarker for the early detection of preclinical type 1 diabetes. University of Antwerp
Validation study of the open ADAMTS13 conformation assay as a novel biomarker for correct diagnosis and predicting relapse in immune mediated thrombotic thrombocytopenic purpura KU Leuven
Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical application Vrije Universiteit Brussel
Titin Antisense-1, a novel therapeutic target and biomarker in heart failure with preserved ejection fraction. KU Leuven
Heart failure with preserved ejection fraction (HFpEF) is an invalidating and deadly disease, mainly affecting women (2:1). Diabetes, hypertension along with obesity and chronic kidney failure are the main treatable co-morbidities. Still, early diagnostic markers or mortality-reducing drugs are completely lacking. Recently we discovered a novel long non-coding RNA, titin antisense-1 (TTN-AS1), as a promising therapeutic target, and female ...